Wed, Apr 30, 8:15 PM (12 days ago)
**Ovid Therapeutics Inc. (OVID) - Summary of 10-K/A Amendment** **Company Overview:** Ovid Therapeutics Inc. (OVID) is a biopharmaceutical company focused on developing therapies for rare neurological disorders. The amendment (10-K/A) includes Part III information due to the delay in filing the definitive proxy statement. **Financial Performance:** - The amendment does not include new financial statements or restatements. - Financial condition and performance details are not provided in this amendment. **Executive Compensation:** - **Jeremy M. Levin (CEO):** Total compensation for 2024 was $2,774,102, including a base salary of $625,296 and significant equity awards. - **Margaret Alexander (President & COO):** Total compensation for 2024 was $1,655,155, including a base salary of $484,417 and equity awards. - **Jeffrey Rona (CFO):** Total compensation for 2024 was $1,518,796, including a base salary of $492,128 and equity awards. **Board and Governance:** - The Board of Directors includes Jeremy M. Levin, Karen Bernstein, Barbara Duncan, Kevin Fitzgerald, Bart Friedman, and Stelios Papadopoulos. - The Audit Committee members are Drs. Bernstein and Poole, Ms. Duncan, and Mr. Friedman, with Ms. Duncan serving as chair. **Risk Factors:** - The amendment does not provide specific risk factors but refers to the initial filing for detailed risk disclosures. **Market Position:** - As of June 30, 2024, the aggregate market value of common stock held by non-affiliates was approximately $45.9 million. - Significant shareholders include Takeda Pharmaceutical Company Limited, Rubric Capital Management LP, and BlackRock, Inc. **Future Outlook:** - The company is pursuing a revised strategic plan, including workforce reductions to manage costs. - The amendment does not provide detailed future outlook information; refer to the initial filing for strategic initiatives. **Changes and Impact:** - The amendment includes Part III information and new certifications from the principal executive and financial officers. - No financial statements or restatements are included, and no changes to previously disclosed information are noted. **Ticker:** OVID **Conclusion:** Ovid Therapeutics Inc. (OVID) filed this amendment to include Part III information due to the delay in filing the definitive proxy statement. The amendment provides details on executive compensation, board governance, and significant shareholders but does not include new financial statements or restatements. For a comprehensive understanding of the company's financial performance, risk factors, and strategic outlook, refer to the initial 10-K filing.